Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.

• Source: Biospace
• 666
• February 11, 2018